The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer

The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer

The emergence of cyclin-dependent kinase (CDK) 4 and 6 inhibitors has brought a new approach in the treatment of advanced hormone receptor (HR) positive breast cancer and human epidermal growth factor (HER) 2 negative breast cancer. To date, three CDK 4/6 inhibitors, palbociclib, ribociclib, and abe...

Full description

Bibliographic Details
Main Authors: Vasiliki Tzelepi C., Aristeidis Gogadis T., Christos Adamidis K., Timotheadou Eleni T.
Format: Article
Language:English
Published: Sciendo 2020-04-01
Series:Forum of Clinical Oncology
Subjects:
breast cancer
cdk4/6 inhibitors
toxicity
drug interactions
clinical management
Online Access:https://doi.org/10.2478/fco-2019-0007

Internet

https://doi.org/10.2478/fco-2019-0007

Similar Items